These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 30089488

  • 1. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study.
    Urakawa H, Yonemoto T, Matsumoto S, Takagi T, Asanuma K, Watanuki M, Takemoto A, Naka N, Matsumoto Y, Kawai A, Kunisada T, Kubo T, Emori M, Hiraga H, Hatano H, Tsukushi S, Nishida Y, Akisue T, Morii T, Takahashi M, Nagano A, Yoshikawa H, Sato K, Kawano M, Hiraoka K, Tanaka K, Iwamoto Y, Ozaki T.
    World J Surg Oncol; 2018 Aug 08; 16(1):160. PubMed ID: 30089488
    [Abstract] [Full Text] [Related]

  • 2. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K, Suehara Y, Okubo T, Sasa K, Kurihara T, Akaike K, Kubota D, Torigoe T, Hasegawa N, Ishii M, Nakamura Y, Kim Y, Takagi T, Kaneko K, Hayashi T, Saito T.
    J Orthop Surg (Hong Kong); 2020 Aug 08; 28(2):2309499020929786. PubMed ID: 32539628
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A, Tsuchiya H, Ishii T, Nishida Y, Abe S, Matsumine A, Kawai A, Yoshimura K, Ueda T.
    BMC Musculoskelet Disord; 2016 Jul 22; 17():306. PubMed ID: 27448567
    [Abstract] [Full Text] [Related]

  • 4. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
    Scoccianti G, Totti F, Scorianz M, Baldi G, Roselli G, Beltrami G, Franchi A, Capanna R, Campanacci DA.
    Clin Orthop Relat Res; 2018 Sep 22; 476(9):1783-1790. PubMed ID: 30778015
    [Abstract] [Full Text] [Related]

  • 5. A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610.
    Urakawa H, Mizusawa J, Tanaka K, Eba J, Hiraga H, Kawai A, Nishida Y, Hosaka M, Iwamoto Y, Fukuda H, Ozaki T.
    Jpn J Clin Oncol; 2019 Apr 01; 49(4):379-382. PubMed ID: 30796832
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.
    Chinder PS, Hindiskere S, Doddarangappa S, Pal U.
    Clin Orthop Surg; 2019 Sep 01; 11(3):352-360. PubMed ID: 31475058
    [Abstract] [Full Text] [Related]

  • 7. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?
    Hindiskere S, Errani C, Doddarangappa S, Ramaswamy V, Rai M, Chinder PS.
    Clin Orthop Relat Res; 2020 Nov 01; 478(11):2522-2533. PubMed ID: 32401001
    [Abstract] [Full Text] [Related]

  • 8. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
    Müller DA, Beltrami G, Scoccianti G, Campanacci DA, Franchi A, Capanna R.
    World J Surg Oncol; 2016 Nov 04; 14(1):281. PubMed ID: 27809843
    [Abstract] [Full Text] [Related]

  • 9. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation.
    Tsukamoto S, Hindiskere S, Honoki K, Mavrogenis AF, Tanaka Y, Chinder PS, Donati DM, Errani C.
    Int Orthop; 2023 Jan 04; 47(1):265-273. PubMed ID: 36282294
    [Abstract] [Full Text] [Related]

  • 10. Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery.
    Asano N, Saito M, Kobayashi E, Morii T, Kikuta K, Watanabe I, Anazawa U, Takeuchi K, Suzuki Y, Susa M, Nishimoto K, Ishii R, Miyazaki N, Mrioka H, Kawai A, Horiuchi K, Nakayama R.
    Ann Surg Oncol; 2022 Jun 04; 29(6):3992-4000. PubMed ID: 35175454
    [Abstract] [Full Text] [Related]

  • 11. Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone.
    Puri A, Gulia A, Hegde P, Verma V, Rekhi B.
    Bone Joint J; 2019 Feb 04; 101-B(2):170-177. PubMed ID: 30700112
    [Abstract] [Full Text] [Related]

  • 12. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
    Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, Donati DM.
    J Bone Joint Surg Am; 2018 Mar 21; 100(6):496-504. PubMed ID: 29557866
    [Abstract] [Full Text] [Related]

  • 13. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
    Tsukamoto S, Tanaka Y, Mavrogenis AF, Kido A, Kawaguchi M, Errani C.
    Clin Orthop Relat Res; 2020 May 21; 478(5):1076-1085. PubMed ID: 31794487
    [Abstract] [Full Text] [Related]

  • 14. Combined preoperative denosumab and adjuvant microwave ablation for high-risk giant cell tumor of bone: a retrospective study in a single center.
    Zheng C, Xu G, Zhou X, Qiu J, Lan T, Zhang S, Li W.
    J Orthop Surg Res; 2024 Aug 17; 19(1):488. PubMed ID: 39154187
    [Abstract] [Full Text] [Related]

  • 15. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
    Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, Palmerini E, Casali P, Gronchi A, Parry M, Campanacci DA, Scoccianti G, Wagrodzki M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R.
    Eur J Surg Oncol; 2018 Sep 17; 44(9):1384-1390. PubMed ID: 29650420
    [Abstract] [Full Text] [Related]

  • 16. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
    Agarwal MG, Gundavda MK, Gupta R, Reddy R.
    Clin Orthop Relat Res; 2018 Sep 17; 476(9):1773-1782. PubMed ID: 30794215
    [Abstract] [Full Text] [Related]

  • 17. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ, Ma TX, Qi DW, Zhao M, Hu T, Zhang GC.
    Orthop Surg; 2019 Dec 17; 11(6):1101-1108. PubMed ID: 31762217
    [Abstract] [Full Text] [Related]

  • 18. Giant cell tumour of bone in the denosumab era.
    van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H.
    Eur J Cancer; 2017 May 17; 77():75-83. PubMed ID: 28365529
    [Abstract] [Full Text] [Related]

  • 19. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
    Perrin DL, Visgauss JD, Wilson DA, Griffin AM, Abdul Razak AR, Ferguson PC, Wunder JS.
    Bone Joint J; 2021 Jan 17; 103-B(1):184-191. PubMed ID: 33380180
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, Razak AR, Griffin AM, Ferguson PC, Wunder JS.
    Eur J Cancer; 2016 May 17; 59():1-12. PubMed ID: 26990281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.